No, they do invitee significant early investors who believe in the Company when it was sub $1 as is common industry practice. And no they are not the only company to limit who attends their Investor/Analyst Day. They have a live broadcast setup, because they probably can't fill a room for 1000 shareholders - all of which are important to and appreciated by the Company. Further, based upon your recent posts, they don't want quacky Q&A's from small foolish day traders or whatever you consider yourself. Now, how bout we zip it.....
I got my invite. Maybe you need to buy more shares so they recognize your seriousness and support of their business model and future plans.
I believe a little bit of both. Some may have hedged part of their longs and some competitors do have deep pockets. Further, the FDA is supposed to respond by Oct 6th but the response could be an extension to review further submissions (or so I learned today). Regardless, AI being immediately marketable moves the price now. Otherwise, Analyst Day will provide clarity of 2015 and new markets while the Epifix trials and other news releases recently are positive and progressing.
14.6m short is eventually a few hundred million dollar loss to those shorts! Be patient. There is something special here and significant value will be realized when the time is right.
Please describe the deal terms. Interesting that mgmt hasn't disclosed them but you "know" better. If you can elaborate, I'd be interested in your thoughts? Exactly - your opinion is like your ID - asse9!
Exponential cash flow from these strategic deals to fund Injectible trials vs. dilution via future stock issuances also protects early/existing shareholders (downside protection).
Yes, patent "applications"...big difference but continued seeds being planted and in this case in the "micronized" arena. That was my point. Thanks for clarification.
Original guidance was actually $90m at the low end in Fall 2013 so to see that they will have done that rev # with Epifix only illustrates their conservative nature. They could do $150m so my point was $7-$7.50 is a reasonable range if FDA temporarily pulls AI.
Congrats - Yahoo dropped SA and now relies on YOU! Keep posting patents as they are approved.
I disagree with you - trading at 5x 2015 rev est of $150m is not expensive. Further, 2014 original guidance assumed 15% of Injectible revs - however, MDXG is going to meet original guidance on Epifix alone. If FDA pulled AI, you can bank it that 2014 guidance gets raised, MDXG reports its first quarterly profit, and it authorizes a larger buyback.
Newly issued patent on Micronized Placenta this AM. Shorts are doomed...see homebuilders link in Market Pulse section. More patents forthcoming.....supporting new rev streams of Epifix and AI.
Shorts are still defending their positions. Anyone want to speculate on volume, number of shares covered and closing price on FDA day?
Possibly biased, but my read on paragraph 2 of the Analyst Day announcement yesterday is that new sales channels will discuss not only the opening of various Medtronic and other wrap applications, but also Amniofix Injectible application lines of business. I believe management already has the green light from the FDA, subject to test, trials, etc but marketing can continue in a limited form and open up as trials produce the necessary scientific "checks" that the FDA is seeking on expanded applications beyond those already performed by physicians.
One could always say management is hedging its bets also.....
Why do you say that? FDA is required to respond within 14 days following the 60 day review period following the FDA submission. I don't even think we are through the 60 day review period.
Study Highlights include:
MiMedx's multilayer amnion/chorion grafts (EpiFix® and AmnioFix®) contain approximately 20 times more growth factors and cytokines than the competitive single layer amnion grafts evaluated in the study.
AmbioDry2®, the MiMedx PURION® Processed single layer amnion, contains four to five times greater amounts of growth factors than the competitive single layer amnion products (DryFlex®, AmnioExCel®, SteriShield™, and SteriShield II™) that were evaluated in the study.
EpiFix® contains four to five times the growth factors in AmbioDry2®.
All single layer amnion grafts that were tested contained substantially fewer growth factors and cytokines, and therefore, will deliver significantly less growth factors and cytokines than MiMedx's amnion/chorion multilayer grafts with the same surface area.
When calculated per surface area of tissue applied to a wound, the evaluated PURION® Processed amnion contained on average only 25% of the growth factor content contained in the PURION® Processed chorion.
The chorion layer in the MiMedx multi-layered allografts is four to five times thicker than the amnion layer, and therefore, contributes disproportionately to the growth factor content in amnion/chorion grafts. Chorion contributes on average 82% of the growth factors in EpiFix®.
First time in 4 months that the trend has moved downward.....should start to get interesting.
Same presentation - See page 20.....2014 guidance was flat BECAUSE of the reclassification of the injectable business being Surgical/Sports ONLY in 2013 and prior WHILE NOW in 2014, it's split between both Surgical/Sports & Wound, because new applications of AI will apply to both segments. Patents pending too! The Company doesn't disclose YTD AI revs to fully make that comparison. One would think drs who used it in 2013 would be reusing an equal or greater amount in 2014.
So I think its misleading to say its stopped in its tracks because the disclosure at bottom of page 20 specifically denotes this change in reporting and prior years haven't been reclassified.
Page 22.....Bullet Point - Finalize negotiations with FDA for injectable platform.
Q314 is going to be very exciting!
Management had to disclose the FDA Untitled letter and was advised by their counsel to do such. Is there any time requirement to disclose the FDA transition letter? So if it was a positive letter, would the Company be required to disclose the letter immediately or could it buy the remaining $10m shares first, then announce?
In May 2014 - repurchased 202,000 shs @ $5.37 avg cost. In June 2014 - repurchased 582,200 shs @ $5.92 avg cost. $5.4 of $10m capacity remained as of 6/30.
Obviously, the Board is compelled to support $5.94 with free cash flow and presumably since that was the avg price, the buy support line is somewhere in the $6's. In time, that support line will move higher....
MDXG like OSIR are debt free. Both have operating payables which are due to timing and normal to operating any business. You are not correct. See both Balance Sheets. MDXG has an Accumulated Deficit of $74m, but OSIR is over $200m as of 3/31/14.